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Abstract
Illicit drug abuse and HIV/AIDS have increased rapidly in the past 10 to 20 years in China. This paper
reviews drug abuse in China, the HIV/AIDS epidemic and its association with injection drug use
(IDU), and Chinese policies on illicit drug abuse and prevention of HIV/AIDS based on published
literature and unpublished official data. As a major drug trans-shipment country with source drugs
from the "Golden Triangle" and "Gold Crescent" areas in Asia, China has also become an
increasingly important drug consuming market. About half of China's 1.14 million documented drug
users inject, and many share needles. IDU has contributed to 42% of cumulatively reported HIV/
AIDS cases thus far. Drug trafficking is illegal in China and can lead to the death penalty. The public
security departments adopt "zero tolerance" approach to drug use, which conflict with harm
reduction policies of the public health departments. Past experience in China suggests that cracking
down on drug smuggling and prohibiting drug use alone can not prevent or solve all illicit drug
related problems in the era of globalization. In recent years, the central government has outlined a
series of pragmatic policies to encourage harm reduction programs; meanwhile, some local
governments have not fully mobilized to deal with drug abuse and HIV/AIDS problems seriously.
Strengthening government leadership at both central and local levels; scaling up methadone
substitution and needle exchange programs; making HIV voluntary counseling and testing available
and affordable to both urban and rural drug users; and increasing utilization of outreach and
nongovernmental organizations are offered as additional strategies to help cope with China's HIV
and drug abuse problem.
Introduction
Illicit drug abuse has become an increasing public health
and social concern in the past decades worldwide. Drug
abuse causes many problems both to individuals and to
societies, including loss of productivity, transmission of
infectious diseases, crime, family and social disorder, and
excessive health care expenditures [1]. Human immuno-
deficiency virus (HIV)/AIDS, associated with injection
drug use (IDU) and needle sharing to a large extent, has
become one of most stunning tragedies in human history.
It has caused more than 20 million deaths, and about 40
million people are living with HIV worldwide thus far,
with Africa as the most afflicted continent [2]. As the most
populous country in the world, China has also observed
Published: 01 February 2006
Harm Reduction Journal 2006, 3:4 doi:10.1186/1477-7517-3-4
Received: 13 October 2005
Accepted: 01 February 2006
This article is available from: http://www.harmreductionjournal.com/content/3/1/4
© 2006 Qian et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Harm Reduction Journal 2006, 3:4 http://www.harmreductionjournal.com/content/3/1/4
Page 2 of 8
(page number not for citation purposes)
rapidly increasing drug abuse and HIV/AIDS occurrence
in the past 10 to 20 years. China can still shape the course
of its epidemic, but it needs to move swiftly and with great
resolve [2].
This paper reviews global illicit drug trafficking, drug
abuse and its association with HIV/AIDS epidemic in
China, and Chinese policies on illicit drug abuse and pre-
vention of HIV/AIDS, and offers additional strategies to
governmental crack down on drug smuggling and drug
use prohibition to help cope with China's HIV and drug
abuse problem. We searched English and Chinese lan-
guage literature via Medline and the China National
Knowledge Infrastructure and reviewed unpublished offi-
cial data, including national reports on illicit drug control
and HIV/AIDS sentinel surveillance data. More than 100
papers and reports were reviewed. Key databases included:
(1) Chinese Journal of Epidemiology (Zhonghua Liu Xing
Bing Xue Za Zhi); (2) Chinese Journal of STD/AIDS Con-
trol and Prevention (Zhongguo Xing Bing Ai Zi Bing Fang
Zhi); and (3) National HIV sentinel surveillance data
1995–2004.
Illicit drug use in China
Drug abuse in China can be traced to the late Qing
Dynasty (1644–1911 A. D.), when British colonists force-
fully brought Indian opium into China for exchange of
silk, tea, and cash. Opium was then locally planned. By
the founding of new China in 1949, more than 20 million
Chinese people were opium addicts, representing 5% of
the total population [3]. After a short nationwide anti-
drug campaign, drug abuse was reported to be eliminated
from the mainland in the early 1950s, and for the next
three decades China was believed to be a drug-free nation
[3].
Illicit drugs reemerged in China in the 1980s as China
adopted an open-door policy, and the reemergence was
mainly connected with global drug trafficking activities.
In Asia, there are two major opiate-producing regions: the
"Golden Triangle," comprising three Southeast Asian
countries of Myanmar (Burma), Laos and Thailand, and
the "Golden Crescent" that includes the three Southwest
Asian nations of Afghanistan, Iran and Pakistan [4,5]. The
majority of heroin and opium in the current Chinese mar-
ket is brought from Myanmar into Yunnan Province or
from Viet Nam into Guangxi Province, and then it is trans-
shipped along inland trafficking routes to Sichuan,
Guizhou, Gansu and Xinjiang or to Guangdong, Shanghai
and Beijing [6-8]. A small potion of heroin/opium is traf-
ficked into Xinjiang from the "Golden Crescent" [8].
These drugs further penetrate into other provinces. Since
the late 1990s, increasing amounts of amphetamine-type-
stimulants (ATS) and other chemically related synthetic
drugs including amphetamine, methamphetamine and
ecstasy have been locally manufactured and consumed in
China [4].
The number of drug users documented officially by Chi-
nese public security departments increased from 70,000
in 1990 to 1.14 million by 2004 [9] while the estimated
number is 3.5 million [1]. The lifetime prevalence rates of
illicit drug use among residents age 15 years or older in
high-prevalence Chinese cities increased from 1.1% in
1993 to 1.6% in 1996, and the 1-year prevalence rate
increased from 0.9% to 1.2% during this period [10,11].
The main drug of choice in China is heroin. According to
a report of the National Narcotic Control Commission
(NNCC), 87.6% of drug users abused heroin in 2002 [12].
The abuse of ATS and MDMA (methylenedioxymetham-
phetamine or ecstasy) has become popular in city night
clubs in recent years [1]. In the 1980s, farmers living in
rural bordering areas in Yunnan and Guangxi provinces
constituted a large fraction of drug users. Since the early
1990s, more and more urban residents use illicit drugs.
The majority of drug abusers are young people with a low
education level and limited job skills, although a small
proportion of urban users regard using drugs as an indica-
tor of "high social class." NNCC data showed that 74%
were aged 17–35 years in 2002 [12].
Experimentation (90%), peer pressure (44%), and relaxa-
tion (42%) are commonly cited reasons for beginning to
use drugs. Initially, drugs were taken primarily through
sniffing/snorting (55%) or smoking cigarettes mixed with
drugs (38%) [13]. Injection of drugs became increasingly
common among drug users, probably as a result of
increasing prices of illicit drugs and greater cost effective-
ness of injecting to achieve the desired effect. National
behavioral surveillance data showed that the median
prevalence of IDU among drug users increased from 35%
in April 1995 to 49% in April 2004, and median preva-
lence of needle sharing among IDUs also increased from
26% to 43% during this period [14,15]. "Buying from
drug or grocery stores" and "buying from hospitals" were
the two most common routes for obtaining injection nee-
dles and syringes [16]. Reasons for sharing a needle
included: "do not care about anything else when
hooked," "thought it had been cleaned up," "difficult to
buy or obtain," "only sharing with selected persons," "no
money to buy," and "following other drug users" [16].
Besides IDU and needle sharing, other risk behaviors
including unprotected commercial sex put drug users and
ultimately non drug users at high risk of HIV [17,18]. It is
believed that many female drug users sell sex for drugs,
and limited published research also provides supporting
evidence [18-20]. However, the impact of the interaction
between IDU and commercial sex on HIV risk is not clear.
Considering the dramatic increase in the commercial sexHarm Reduction Journal 2006, 3:4 http://www.harmreductionjournal.com/content/3/1/4
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industry in China, and the potential bridging role of those
with dual risk behaviors in transmitting HIV from high
risk groups to the general population, research on the
interaction of IDU and commercial sex should be given
high priority.
HIV/AIDS epidemic and its association with IDU 
in China
Since the first AIDS case was detected in 1985 [21], China
has cumulatively reported about 100,000 HIV infections
by 2004 [22]. Thus far, the HIV/AIDS epidemic is mainly
concentrated in specific geographical areas and sub-group
populations [23]. IDU has been the largest contributor to
the reported epidemic since 1989, when the first HIV out-
break among IDUs was observed in Ruili City of Yunnan
Province bordering with Myanmar [24]. All 31 provinces,
autonomous regions and municipalities on mainland
China reported HIV infections among IDUs by 2002, and
42% of infections in China were estimated to be due to
IDU by 2004 [22].
In 1995, only one out of 8 national sentinel sites for IDU
detected HIV infections. The detected prevalence was
0.02% [14]. By 1997, 3 out of 22 sites detected positives,
and the average prevalence increased to 6.6%. After that,
national average HIV prevalence among IDUs varied
between 5.4% and 8.2% [15,22]. However, dramatic geo-
graphic differences in HIV prevalence have been observed.
Yunnan and Xinjiang provinces have the most severe HIV
infection rates among IDUs. Other provinces along or
close to drug trafficking roads, such as Guangxi, Sichuan,
Guizhou, Hunan, and Jiangxi, have moderate epidemics
[25]. HIV began to spread rapidly in Yunnan province in
the late 1980s and early 1990s [26]. High prevalence
among IDUs was first detected in 1998 in Urumqi City
(28.8%) and in Yining City (82.2%) of Xinjiang Province
and later on in selected sentinel sites for IDU in other
provinces [27]. These include Guangxi (>10%, 1998 sen-
tinel data), Jiangxi (14.5%, 2000), Sichuan (16–20%,
2002), Guizhou (17–19%, 2002), and Hunan (15–20%,
2003) [23]. In 2004, 75% of HIV national sentinel sites
for IDU detected HIV infection. More than 20% of HIV
prevalence was reported in selected sites in Xinjiang,
Sichuan, Guizhou, Guangxi and Hunan [22]. Official HIV
prevalence rates in other geographic areas remain <10%;
these reports may reflect reality or may be due to failure in
detection.
At least 7 HIV-1 subtypes (A, B/B', C, D, E, F, and G), and
3 major circulating recombinant forms (CRF01_AE,
CRF07_BC, and CRF08_BC) have spread in China [28-
31]. However, the most prevalent HIV-1 strains are sub-
type B' (44%), C (29%, usually CRF08_BC) and
CRF01_AE (13%) [30]. Subtype C and B'/B are the main
subtypes among IDUs [30,32]. Co-circulating of multiple
subtypes of HIV-1 in China implies the possibility of
interclade recombination. Characterization of genetic var-
iability of HIV-1 may help track the epidemic, generate
subtype-specific immunological reagents, develop vac-
cines, and choose antiretroviral therapy regimens.
Chinese policies on illicit drug control and 
related HIV/AIDS prevention
Drug trafficking and abuse are illegal in China. Offenders
may be sentenced to prison if smuggling 10 grams or
more of heroin and could receive the death penalty for
smuggling more than 50 gram of heroin. In 1990, the
"Regulations on Prohibition Against Narcotics" were
enacted with three levels of penalty to be applied to drug
users. First-time offenders may be fined and/or allowed to
go to voluntary detoxification centers, where they receive
10-day methadone treatment managed by the Ministry of
Public Health. The cost of treatment is about 2,000 to
5,000 Chinese yuan – a cost considered expensive for
many drug users and their families. If drug users who have
gone through a voluntary detoxification program are
caught again using drugs, they are sent to compulsory
rehabilitation centers (CRC) administered by the Ministry
of Public Security for 6 to 12 months. Drug users who
relapse users after going through CRC are sent to reeduca-
tion-through-labor-centers (RELC) administered by the
Justice Department for two to three years [33].
In Chinese history, drug abuse and prostitution have been
considered "social evils." The Chinese government typi-
cally takes "crackdown" measures and tries to eradicate
these phenomena. China did achieve a success story in the
1950s. Illicit drug abuse and prostitution were eradicated
through national anti-drug and anti-prostitution cam-
paigns [3,34]. However, this success has not been
repeated in the past two decades. One possible explana-
tion is that China has expanded its market economy and
opened further to the outside world. Under this situation,
it seems impossible to completely stem manufacture of
highly profitable illicit drugs and import of drugs along
China's long porous land borders with drug-producing
countries.
Currently, the Chinese government adopts more prag-
matic policies and takes measures targeting both the root
and surface of the drug abuse problem. The measures tar-
geting the root include continuously cracking down on
drug smuggling activities and discouraging new users
through anti-drug education campaigns. The Chinese gov-
ernment actively seeks to collaborate with neighboring
countries to prevent drug smuggling across borders and to
help Myanmar, for example, to reduce opium poppy cul-
tivation by replacing with crop plantation. Chinese mass
media have increased anti-drug education to the general
population. Anti-drug education has been included in theHarm Reduction Journal 2006, 3:4 http://www.harmreductionjournal.com/content/3/1/4
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curricula for primary and secondary school students [9].
The measures targeting the surface include providing drug
detoxification and harm reduction services to drug users.
China has about 300 voluntary detoxification clinics, 700
CRC, and 200 RELC. Each can accommodate 100 to 3,000
patients [9]. Both western medications and traditional
Chinese medicines are used for detoxification, and com-
munity therapy has been provided in some heavily
affected areas since the late 1990s [9]. The National Work-
ing Group for Community-based Methadone Mainte-
nance Therapy was established collectively by the Ministry
of Health, the Ministry of Public Security, and the State
Food and Drug Administration. Guidelines for metha-
done maintenance therapy and needle exchange pro-
grams were enacted in early 2004. By the end of 2004,
there were 34 methadone substitution therapy clinics and
90 clean needle exchange service points across the country
[35,36]. The methadone program will be expanded to
about 1,000 sites and treat 200,000 drug users over the
next 5 years [35].
Conclusions and recommendations
Whether or not China can shun a generalized epidemic of
HIV/AIDS may be largely dependent on how China deals
with IDU risk factors and breaks the bridge between IDU
and heterosexual transmission. Past experience in China
suggests that solely cracking down on drug smuggling and
prohibiting drug use can not prevent or solve all illicit
drug related problems in the era of globalization. Govern-
mental support, harm reduction programs, voluntary
counseling and testing, and utilization of non-govern-
mental organizations are recommended.
Strengthening government's leadership at both central and 
local levels
China has a strong central government. Without govern-
ment support, it would be not imaginable to achieve suc-
cess in the campaigns against drug use and the spread of
HIV/AIDS. Since the late 1990s, the Chinese central gov-
ernment has stepped up HIV/AIDS control efforts, includ-
ing setting out national policy framework for responding
to HIV/AIDS, increasing funding inputs, expanding col-
laborations with international organizations. The Chinese
National Medium-and-Long-Term Strategic Plan for AIDS
Prevention and Control (1998–2010) was formulated in
1998 and set one goal that "by 2002, health education on
preventing HIV/AIDS and STDs should be carried out at
all detoxification centers and re-education centers as well
as in 80% of jails..." [37]. The Action Plan (2001–2005)
calls for creating "drug-free communities" through drug
prohibition education and drug detoxification activities,
together with active promotion of healthy life styles and
behaviors and harm reduction for drug users.
On the other hand, there is substantial autonomy at pro-
vincial level in some areas. Responses to drug use and
HIV/AIDS epidemic vary significantly at provincial and
lower administrative levels. For example, Yunnan and
Guangxi provinces have done far more than other prov-
inces in supporting, implementing, and advocating for
harm reduction interventions for IDUs. Some local gov-
ernments are not fully motivated to confront drug abuse
and HIV/AIDS problems. Some government leaders still
ignore or even cover up these problems. They are far more
interested in economic growth than HIV/AIDS control
and wish for their administrative areas to become "econ-
omy provinces" or "economy cities" rather than "AIDS
provinces" or "AIDS cities," which is believed to be help-
ful for their career promotion. Advocacy to and support
from government leaders at all administrative levels for
harm reduction and community-based prevention are
needed.
Scaling up methadone substitution and needle exchange 
programs
Harm reduction includes many strategies, such as metha-
done maintenance, needle exchange, dispensing other
drugs, and outreach services [38]. Harm reduction has
been a controversial issue as compared to abstinence-
based philosophies [39,40]. Harm reduction seems to
encourage tolerance of social phenomena that are unde-
sirable and hazardous and that may result in social turpi-
tude. Instead, abstinence is considered to be the proper
way to address drug problems [39]. In the United States,
law and policy restrict the use of federal funds in support-
ing needle and injection equipment distribution projects.
However, many studies refute the concern that access to
sterile syringes is an endorsement of IDU and is likely to
result in increases in injection and initiation of injection
[41,42]. Harm reduction projects in China are in the pilot
phases. Some scholars and health officials still have simi-
lar concerns as in some Western countries. They believe
that needle exchange services may send a wrong signal of
encouraging drug abuse to drug users and the public, and
they consider methadone substitution unethical because
it uses one drug to replace another drug [43]. As drug use
and HIV/AIDS spread rapidly across the country, it is
urgent to find supporting domestic evidence that harm
reduction will reduce HIV transmission by evaluating
harm reduction projects and ultimately scaling up harm
reduction efforts.
It is easy to access sterile needles and syringes in urban
areas of China because they are legally sold and available
at pharmacies and medical clinics [16,44]. However,
many drug users live in rural areas; in addition, drug users
may share needles and syringes because they can not buy
them during night time or do not have money to buy
them [16]. Methadone is orally administered, and metha-Harm Reduction Journal 2006, 3:4 http://www.harmreductionjournal.com/content/3/1/4
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done substitution can reduce injection and needle sharing
of opiate drug addicts. But methadone maintenance ther-
apy is costly and requires drug users to attend clinics on a
regular basis. Therefore, methadone substitution and nee-
dle exchange services should be made available and
affordable at convenient times and in both urban and
rural settings, especially in the communities with heavy
drug use.
In addition to cost and availability, other factors might
also affect acceptability of methadone maintenance ther-
apy, such as concerns about the safety and efficacy of the
therapy [45]. Greater retention in treatment has been
found to result in greater decreases in drug use, criminal
activity, and unemployment [46]. The length of drug
treatment has a positive association with better post-treat-
ment outcome [46]. However, limited experience with
methadone maintenance therapy (MMT) in China shows
a high rate of dropouts. International studies have shown
that motivational enhancement therapy or motivational
interviewing enhances treatment initiation, retention and
outcomes in MMT program [47,48], and adding behavio-
ral intervention components into MMT programs
increases abstinence and reduces HIV risk behaviors [49].
Policy-oriented operational research is needed in China to
better understand how to increase the effectiveness of
MMT and other harm reduction interventions in the Chi-
nese context.
There are still persistent conflicts in the policy and legal
landscape. The central government has given explicit sup-
port to harm reduction, for example, as stated in the
Medium- and Long-Term Strategic Plan and the Action
Plan. Some programs have been implemented success-
fully [36,50,51]. However, in China, as in many other
countries, public health and public security authorities
frequently approach drug abuse from different perspec-
tives, leading to conflicting approaches at local levels. The
crackdown philosophy and detention of drug users in
China reflect inconsistent interpretations of "harm reduc-
tion" and present a challenge to public health officials in
implementing methadone substitution and needle-
exchange programs [52]. Drug users may be reluctant to
participate in these programs due to fear of being caught
by police officers [50]. It might be impossible to com-
pletely solve the dilemma in the near future, but this con-
flict is expected to gradually reduce for the following
reasons. First, Chinese national policies for HIV preven-
tion and control have become much more pragmatic in
the past years. MMT and needle exchange programs were
almost unimaginable several years ago, but now they are
ready to be expanded across the country. We expect that
the open policy trend will continue as the Chinese econ-
omy is increasingly merged with international markets,
and this trend will favor harm reduction programs. Fur-
thermore, China's centralized government may achieve an
advantage in promoting public health policies if these
policies are believed to be correct. Second, inter-agency
coordination on public health crisis has been enhanced at
both central and local governmental levels since SARS
outbreak in 2003, which reduces potential conflict of pub-
lic health policies. Public health workers should provide
policy advocacy to public security authorities and help
them change their traditional norms about illicit drug
control and obtain their supports for harm reduction.
Third, operational research is needed to provide evidence
on the benefits of harm reduction programs and convince
policy enforcers and lead to revision of unfavorable policy
components.
HIV voluntary counseling and testing
HIV voluntary counseling and testing (VCT) is often con-
sidered the first step for initiating prevention and/or ther-
apy. One of the strategies for addressing the AIDS
epidemic is to give people an opportunity to know their
HIV status so that they can take precautions to avoid fur-
ther spread and receive early therapy if they are infected
[53,54]. However, even in developed countries, many at-
risk people do not take VCT. A national British survey in
2000 showed that only one-third of IDUs had VCT in the
past 5 years [55]. About one-fourth of the 0.8 to 0.9 mil-
lion infected people in the United States remain unaware
that they are HIV positive [54]. In China, there is a large
discrepancy between reported (about 100,000) and esti-
mated (about 1 million) cumulative HIV/AIDS cases thus
far. Many at-risk individuals do not seek out standard HIV
counseling and testing services. The stigma associated
with drug use and HIV/AIDS and fear of arrest or knowing
a positive result can be major barriers to access to VCT. A
survey among 840 pregnant women and 780 health pro-
fessionals in Yunnan Province – an epicenter of the HIV/
AIDS epidemic in China – found prevalent negative atti-
tudes toward HIV/AIDS. Twenty-three percent of health
professionals and 45% of pregnant women thought HIV
was a disease of "low class and illegal" people; 48% of
health professionals and 59% of pregnant women
thought that HIV positive individuals should not be
allowed to get married; and 30% of the health profession-
als were not willing to treat an HIV-positive individual
[56]. Cost of traditional VCT, low awareness of risk factors
for HIV infection, distance, and inconvenience in time
also may prevent access to VCT. Possible solutions include
development of outreach programs to offer anonymous
testing and counseling to those at heightened risk of HIV
infection and adoption of new technologies such as rapid
saliva testing and counseling strategies to improve the
outreach and efficacy of programs.Harm Reduction Journal 2006, 3:4 http://www.harmreductionjournal.com/content/3/1/4
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Outreach and non-governmental organizations
Non-governmental organizations (NGO) can play a criti-
cal role in the delivery of HIV prevention services and
other assistance to persons living with AIDS. The flexibil-
ity of NGOs enables them to respond quickly to fill in
gaps in health care and social services. NGOs can do what
government agencies cannot do or are not willing to do –
for example, reaching out without perceived threat to
IDUs and other marginalized sub-groups whose behav-
iors are often stigmatized and also put them at higher risk
of HIV/AIDS. A recent survey of 29 NGOs in Central and
Eastern Europe showed that most NGOs targeted injec-
tion drug users; provided needle exchange and HIV pre-
vention peer education; and delivered AIDS presentations
and distributed educational materials [57]. In Africa,
where the main transmission occurs via heterosexual
activity, NGOs are most likely to direct their attention to
the general public and to youth; they provide peer-educa-
tion or community outreach [58]. In both Thailand and
Brazil, where success has been observed in controlling the
HIV/AIDS epidemic or reducing AIDS mortality, NGO are
believed to play a key role, but their programs lack rigor-
ous and systemic evaluation [59,60]. NGOs often face sev-
eral difficulties: lack of financial resources [57,58]; lack of
communications with governmental organizations [61];
governmental indifference or opposition; and AIDS-
related stigma [57].
China has large number of government organized NGOs
(GONGOs), including Family Planning Associations,
Women's Federation, Red Cross, Youth League, trade
unions, and diverse academic associations. The members
in these GONGOs have formal positions in governmental
organizations while they volunteer at GONGOs. The
"true" NGO that has no relationship to the government is
just emerging in China. More and more of existing Chi-
nese GONGOs are getting involved in sexually transmit-
ted disease/AIDS prevention. Since the 1990s, the Chinese
government has encouraged them to participate in HIV/
AIDS control. These government-sponsored NGOs sup-
port HIV/AIDS education and academic publications and
participate in AIDS research and education with foreign
governmental and non-governmental partners, and they
can serve as a powerful aid to the Chinese government to
achieve the goal of stopping further spread of drug use
and HIV/AIDS epidemic.
In spite of its potential for greatly contributing HIV pre-
vention in China, there is little literature in this area. An
exception is a recent study (Chen and Liao, 2005) of a
Women Federation's HIV prevention program in south
China. The study showed that the Women Federation was
able to deliver a culturally oriented, multi-level interven-
tion program targeted at female drug users. The data also
indicated that the program was successfully in increasing
knowledge about HIV/AIDS, increasing condom use, and
decreasing needle and syringe sharing among the female
drug users in the project. Studies which systematically
evaluate the implementation and effectiveness of NGO
based intervention programs are greatly needed in the
future.
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